| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,968 |
10,756 |
$447K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
5,717 |
3,102 |
$300K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,518 |
3,433 |
$221K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
5,715 |
3,101 |
$100K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,046 |
960 |
$71K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,893 |
2,188 |
$67K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,908 |
2,489 |
$64K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
800 |
473 |
$40K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
2,040 |
938 |
$39K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,088 |
1,038 |
$39K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
778 |
687 |
$27K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,029 |
4,700 |
$26K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
697 |
590 |
$25K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,829 |
1,174 |
$16K |
| 87070 |
|
3,431 |
3,188 |
$15K |
| 99305 |
|
454 |
415 |
$14K |
| 87184 |
|
3,193 |
2,967 |
$9K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
113 |
104 |
$7K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
586 |
397 |
$6K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
205 |
109 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
360 |
344 |
$5K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
58 |
58 |
$4K |
| 36410 |
|
543 |
510 |
$4K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
12 |
12 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
156 |
144 |
$3K |
| 93000 |
|
128 |
126 |
$2K |
| 81000 |
|
468 |
441 |
$1K |
| 99000 |
|
329 |
254 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
107 |
98 |
$1K |
| 94760 |
|
5,993 |
5,157 |
$928.66 |
| 71046 |
Radiologic examination, chest; 2 views |
48 |
34 |
$637.92 |
| 90686 |
|
167 |
154 |
$573.15 |
| 99304 |
|
16 |
13 |
$501.86 |
| 99050 |
|
116 |
114 |
$435.26 |
| 2010F |
|
68 |
59 |
$265.00 |
| 36415 |
Collection of venous blood by venipuncture |
1,040 |
959 |
$249.36 |
| 85018 |
|
85 |
85 |
$190.68 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
184 |
180 |
$103.03 |
| 99051 |
|
44 |
43 |
$70.49 |
| 99080 |
|
45 |
38 |
$0.00 |